Latest net income for PASG: $-36M, below the Healthcare sector average of $16B.
Get informed when a big investor buys or sells
+ FollowAs of Jun 2026
Trailing 12 months ending Jun 2026
Loading...
Loading...
Passage Bio (PASG) currently reports a net income of $-36M as of June 2026. That compares with $-57M in the prior-year period — up 36.5% year over year. That is below the Healthcare sector average of $16B. Use the charts on this page to explore Passage Bio's net income history and peer comparisons.
Passage Bio's net income increased from $-57M to $-36M — a 36.5% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Passage Bio's net income of $-36M is lower than the Healthcare sector average of $16B. That is roughly 100.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
Passage Bio reported $-36M in net income as of June 2026. That compares with $-57M in the prior-year period — up 36.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current net income of $-36M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $16B. From there, open related valuation or income-statement pages for Passage Bio, and consider following PASG for alerts when major investors trade the stock.